SequelSEC

ORTHOPEDIATRICS CORP KIDS

Surgical & Medical Instruments & Apparatus · CIK 0001425450 · Fiscal year ends 1231

Revenue
$236.35M
Fiscal year ended 2025-12-31
Operating income
-$39.24M
Fiscal year ended 2025-12-31
Free cash flow
-$15.96M
Fiscal year ended 2025-12-31

ORTHOPEDIATRICS CORP (KIDS) reported revenue of $236.35M and net income of -$39.65M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ORTHOPEDIATRICS CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

ORTHOPEDIATRICS CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$236.35M$204.73M$148.73M$122.29M$98.05M$71.08M$72.55M$57.56M$45.62M$37.30M
Cost of revenue$63.69M$56.13M$37.48M$31.63M$24.65M$16.05M$17.93M$14.88M$11.17M$10.93M
Gross profit$172.66M$148.60M$111.25M$90.66M$73.40M$55.03M$54.62M$42.68M$34.45M$26.37M
Operating income-$39.24M-$35.01M-$26.75M-$25.40M-$18.02M-$26.76M-$9.08M-$9.55M-$6.47M-$6.13M
Net income-$39.65M-$37.82M-$20.97M$1.26M-$16.26M-$32.94M-$13.73M-$12.02M-$8.93M-$6.57M
Research & development$9.10M$11.03M$10.90M$8.45M$5.54M$5.27M$5.75M$4.73M$3.42M$2.22M
Weighted-average diluted sharesshares 23.46Mshares 23.08Mshares 22.68Mshares 20.95Mshares 19.27Mshares 18.06Mshares 14.62MUnavailableUnavailableUnavailable
Pretax income-$39.19M-$41.93M-$21.31M-$3.69M-$17.39M-$33.67M-$12.68M-$12.02M-$8.95MUnavailable
Income tax expense$460.00K-$4.11M-$338.00K-$4.95M-$1.13M-$723.00K$0$0$0$0
Diluted EPS$-1.69$-1.64$-0.92$0.06$-0.84$-1.82$-0.94UnavailableUnavailableUnavailable
Selling, general & administrative$192.56M$167.08M$126.12M$104.00M$85.73M$70.17M$57.95M$47.50M$37.50M$28.29M
General & administrative$119.83M$102.79M$73.30M$57.90M$46.06M$38.32M$26.66M$20.94M$16.97M$11.63M
Selling & marketing$72.73M$64.30M$52.82M$46.09M$39.67M$31.85M$31.28M$26.56M$20.53M$16.66M

Balance

ORTHOPEDIATRICS CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$19.56M$43.82M$31.06M$8.99M$7.64M$28.76M$70.78M$60.69M$42.58M$1.61M
Total assets$508.63M$473.21M$438.74M$427.73M$304.27M$320.41M$182.15M$112.10M$82.30M$30.68M
Current assets$256.42M$237.17M$226.50M$226.72M$133.65M$158.43M$128.06M$97.16M$69.56M$20.83M
Total liabilities$162.03M$118.64M$61.72M$49.08M$78.90M$85.64M$39.79M$30.37M$34.81M$24.68M
Current liabilities$46.20M$33.96M$41.67M$30.87M$29.72M$35.03M$13.66M$9.22M$9.47M$7.25M
Total equity incl. NCI$346.60M$354.57M$377.02M$378.65M$225.37M$234.77M$142.36M$81.73M$47.50M-$65.31M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$71.30M
Inventory$133.79M$117.00M$105.85M$78.19M$57.57M$52.99M$38.00M$25.71MUnavailableUnavailable
Accounts receivable$53.84M$42.36M$34.62M$24.80M$17.94M$17.21M$16.00M$9.00M$5.60M$4.10M
Goodwill$109.27M$93.84M$83.70M$86.82M$72.35M$70.51M$13.77M$0UnavailableUnavailable
Long-term debt$99.82M$72.96M$9.91M$763.00K$907.00K$1.04M$26.07M$21.16M$25.34M$17.43M
Accounts payable$18.79M$8.91M$12.65M$11.15M$9.32M$10.04M$6.47M$3.97M$5.50M$3.54M

Cash flow

ORTHOPEDIATRICS CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$4.85M-$27.05M-$27.05M-$21.77M-$13.06M-$18.53M-$17.77M-$15.58M-$7.22M-$1.12M
Capital expenditures$11.11M$14.26M$16.88M$10.03M$8.10M$10.50M$11.82M$5.25M$5.21M$4.35M
Investing cash flow-$43.63M-$13.16M$41.68M-$113.37M-$7.41M-$69.69M-$61.92M-$5.96M-$6.54M-$4.75M
Financing cash flow$23.98M$53.14M$7.30M$135.97M$6.00K$46.73M$91.02M$39.66M$54.73M$3.60M
Net change in cash-$24.16M$12.75M$22.56M$1.46M-$21.13M-$41.90M$11.34M$18.11M$40.97M-$2.27M
Stock-based compensation$17.78M$13.55M$10.53M$6.68M$5.84M$6.20M$2.60M$3.18M$3.48M$1.25M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$5.96M$0
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$21.12M$19.08M$17.38M$13.10M$10.68M$8.01M$4.67M$2.89M$2.40M$1.90M

Derived

ORTHOPEDIATRICS CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$15.96M-$41.31M-$43.92M-$31.80M-$21.17M-$29.03M-$29.58M-$20.84M-$12.42M-$5.47M
Gross margin73.1%72.6%74.8%74.1%74.9%77.4%75.3%74.2%75.5%70.7%
Operating margin-16.6%-17.1%-18.0%-20.8%-18.4%-37.6%-12.5%-16.6%-14.2%-16.4%
FCF margin-6.8%-20.2%-29.5%-26.0%-21.6%-40.8%-40.8%-36.2%-27.2%-14.7%
SBC / revenue7.5%6.6%7.1%5.5%6.0%8.7%3.6%5.5%7.6%3.4%
Current ratio5.55x6.98x5.44x7.34x4.50x4.52x9.37x10.54x7.35x2.87x
Revenue YoY growth15.4%37.6%21.6%24.7%37.9%-2.0%26.0%26.2%22.3%Unavailable
Net margin-16.8%-18.5%-14.1%1.0%-16.6%-46.3%-18.9%-20.9%-19.6%-17.6%
R&D / revenue3.9%5.4%7.3%6.9%5.7%7.4%7.9%8.2%7.5%6.0%
CapEx / revenue4.7%7.0%11.3%8.2%8.3%14.8%16.3%9.1%11.4%11.7%
Long-term debt / equity0.29xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KIDS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-03-04View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.